A new practical control guide for respiratory disease [DL1] [RP2] in cattle can help UK farmers avoid economic losses as a result of the disease, which is estimated to cost the UK cattle industry £80 million annually. 
The range of products from our Human Healthcare has the unrivalled reputation for quality that is already possessed by Norbrook’s® veterinary products and as always we promise affordable excellence.
Norbrook incorporates a broad spectrum of pharmaceutical preparations, from hospital physician to the general practitioners surgery and to the pharmacist over the counter. Our company possesses the infrastructure to deal efficiently as a global organisation with the necessary experience and benefits flowing from research, and the culture and practical knowledge flowing from manufacture.
Due to our on-going capital investment programme, the range of facilities at Norbrook is constantly being enhanced and we now have capacity available in several of our manufacturing areas, including our human healthcare division. These facilities are designed to meet the demands of the future and combine substantial economies of scale for the largest distributor while still providing the flexibility to cater for the particular needs of specific and perhaps smaller market niches.
Norbrook has recognised the synergies which exist between the manufacture and distribution of veterinary and human medicines and has subsequently expanded into human medicines in recent years. Its expertise in research and development, regulatory and licensing protocols, active substance and finished product development has enabled the company to make a seamless and successful entry into the human medicine market.
The breadth of experience is illustrated by the range of formulation technologies employed in its existing products including a large range of injectable, oral and topical products. State-of-the-art clean room facilities for aseptic manufacture and an on-going programme of primary materials manufacture complete a core of resources to carry forward its development of new product ranges.
Worldwide the Company is divided into three divisions:
1. Veterinary finished dose form.
2. Medical finished dose form.
3. Bulk pharmaceutical raw material for veterinary and medical use.
Norbrook has the technology, facilities and experience to enable any company to move forward in human medicines.
If you would like further information on our Human Healthcare manufacturing facilities, please contact us on:
Tel: +44 28 3026 4435
Please note: Product information presented on this website is intended only as a brief summary of Norbrook products for your convenience. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information you should always consult a healthcare professional from your region. Please see our terms and conditions for further information.
If you are a veterinary surgeon and would like additional information on any of our products please email email@example.com